Talsaclidine
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
1
Sites
0
Countries
0
Endpoints
28
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 28 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 12 of 28 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
6
3
3
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02249403Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type | Talsaclidine Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 0 | Jan 2000 | - | |
| NCT02249351Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type | Talsaclidine Alzheimer’s disease | Alzheimer's disease | Ph 2 | Terminated | 0 | May 2000 | - | |
| NCT02248116Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type | Talsaclidine Alzheimer’s disease | Study partner/caregiver required | Ph 2/3 | Terminated | 0 | Sep 2000 | - |
Showing 1-3 of 3 trials